

Systemic Anti-Cancer Therapy Protocol

Obinutuzumab and CHOP

Previously Untreated Follicular Lymphoma

PROTOCOL REF: MPHACHOHA
(Version No: 1.0)

Approved for use in:

Obinutuzumab in combination with CHOP is recommended as an option for **untreated advanced follicular lymphoma (FL)** in adults (that is, first as induction treatment with chemotherapy, then alone as maintenance therapy), only if the person has a Follicular Lymphoma International Prognostic Index (FLIPI) score of 2 or more.

- The patient has a confirmed histological diagnosis of grade 1-3a CD20 –positive FL
- The patient has bulky stage II disease (>7cm) or stage III disease or stage IV disease.
- No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed
- ECOG PS 0-2

Blueteq registration required: see blueteq for full eligibility criteria

Dosage:**Cycle 1:**

Drug	Dosage	Route	Frequency
Obinutuzumab	1000mg	IV infusion	Day 1
Cyclophosphamide	750mg/m ²	IV infusion	Day 1
Doxorubicin	50mg/m ²	IV infusion	Day 1
Vincristine *	1.4mg/m ² (max 2mg dose)	IV infusion	Day 1
Prednisolone	100mg	Orally	Days 1-5
Obinutuzumab	1000mg	IV infusion	Day 8
Obinutuzumab	1000mg	IV infusion	Day 15

Issue Date: 13 th September 2019 Review Date: September 2022	Page 1 of 11	Protocol reference: MPHACHOHA
Author: Hannah Greaves	Authorised by: Drug & Therapeutics Committee/ Dave Breen	Version No: 1.0

Cycle 2-6

Drug	Dosage	Route	Frequency
Obinutuzumab	1000mg	IV infusion	Day 1
Cyclophosphamide	750mg/m ²	IV infusion	Day 1
Doxorubicin	50mg/m ²	IV infusion	Day 1
Vincristine*	1.4mg/m ² (max 2mg dose)	IV infusion	Day 1
Prednisolone	100mg	Orally	Days 1-5

* For those patients >70, consider vincristine dose of 1mg.

Cycle 7 and 8

Drug	Dosage	Route	Frequency
Obinutuzumab	1000mg	IV infusion	Day 1

Each cycle is a 21 day cycle up to a maximum of 8 cycles

Patients may then be eligible for Obinutuzumab maintenance therapy – please refer to separate protocol.

Administration:

- Obinutuzumab is for intravenous use and should be given as an intravenous infusion through a dedicated line after dilution.
- If a planned dose of obinutuzumab is missed, it should be administered as soon as possible; do not omit it or wait until the next planned dose.
- Obinutuzumab should not be administered as an intravenous push or bolus.
- Obinutuzumab has no or negligible influence on the ability to drive and use machines. IRRs are very common during the first infusion, and patients experiencing infusion related symptoms should be advised not to drive or use machines until symptoms abate.
- Doxorubicin hydrochloride may cause a red colour to the urine. Patients should be warned that this does not pose any health hazards.
- Maximum cumulative dose of doxorubicin: 450-550 mg/m²

Issue Date: 13 th September 2019 Review Date: September 2022	Page 2 of 11	Protocol reference: MPHACHOHA
Author: Hannah Greaves	Authorised by: Drug & Therapeutics Committee/ Dave Breen	Version No: 1.0

Emetogenic risk:

Highly emetogenic

Supportive Treatments:

Pre-medication: (see treatment schedule table below)

- Paracetamol orally 1g to be taken 30 minutes prior to the infusion
- Chlorphenamine intravenously 10mg to be taken 30 minutes prior to the infusion
- Intravenous dexamethasone should be administered at least 60 minutes prior to the first dose of obinutuzumab (cycle 1, day 1).
- Patients with Grade 3 IRRs with the previous infusion OR those with a lymphocyte counts $> 25 \times 10^9/L$ prior to the next treatment should have intravenous dexamethasone 20mg 60 minutes prior to the infusion. Please note that the IV dexamethasone may be omitted if Day 1 or oral prednisolone (100mg) taken at least 60 minutes before start of obinutuzumab infusion.

Take home medication:

- Ondansetron 8mg two times a day for 5 days
- Metoclopramide 10mg three times a day when required
- Docusate 100mg two times a day when required
- Filgrastim (G-CSF, e.g. Zarzio) if required, as secondary prophylaxis. Dose is weight dependent. To start on day 5 and administer subcutaneously once daily for 5 days.
- Allopurinol 300mg daily (reduce dose if the patient has renal dysfunction) for the first two cycles.

Extravasation risk:

Obinutuzumab – neutral

Cyclophosphamide – non-vesicant

Doxorubicin – vesicant

Vincristine - vesicant

Refer to the CCC policy for the ‘Prevention and Management of Extravasation Injuries’

Issue Date: 13 th September 2019 Review Date: September 2022	Page 3 of 11	Protocol reference: MPHACHOHA
Author: Hannah Greaves	Authorised by: Drug & Therapeutics Committee/ Dave Breen	Version No: 1.0

Dosing in renal and hepatic impairment:

Renal	Obinutuzumab	No dose adjustment is required in patients with mild to moderate renal impairment (creatinine clearance > 30mL/min). The safety of obinutuzumab has not been established in patients with severe renal impairment (patients with a creatinine clearance < 30mL/min).	
	Cyclophosphamide	Decreased renal excretion may result in patients with severe renal impairment	
		CrCl (mL/min)	Recommended Dose
		> 20	No dose reduction
		10-20	25% dose reduction
Doxorubicin	No dose reduction necessary		
Vincristine	No dose reduction necessary		

Hepatic	Obinutuzumab	The safety and efficacy of obinutuzumab in patients with impaired hepatic function has not been established.	
	Cyclophosphamide	No dose reduction necessary	
	Doxorubicin	General dose adjustment recommendations in patients with hepatic function impairment are based on serum bilirubin concentrations	
		Parameter	Recommended Dose
		AST 2-3 x ULN	25% dose reduction
		Bilirubin 21-50µmol/L OR AST > 3 x ULN	50% dose reduction
		Bilirubin 51-85µmol/L	75% dose reduction
Bilirubin > 85µmol/L	Omit		
Vincristine	Parameter	Recommended Dose	
	Bilirubin 26-51µmol/L OR AST/ALT 60-80	50% dose reduction	
	Bilirubin > 50µmol/L AND AST/ALT normal	50% dose reduction	
	Bilirubin > 51µmol/L AND AST/ALT > 180	Omit	

Interactions:

- No formal drug-drug interaction studies have been performed with obinutuzumab

Issue Date: 13 th September 2019 Review Date: September 2022	Page 4 of 11	Protocol reference: MPHACHOHA
Author: Hannah Greaves	Authorised by: Drug & Therapeutics Committee/ Dave Breen	Version No: 1.0

- Mould active azoles (e.g. posconazole) should be avoided in combination with vincristine as there is an increased risk of neurotoxicity. Fluconazole can be given but signs of neurotoxicity should be monitored.
- Phenytoin given with vincristine and/or doxorubicin may reduce blood levels of the anticonvulsant and to increase seizure activity. Therapeutic Drug Monitoring (TDM) for phenytoin would be advised.
- Concomitant administration of inhibitors of CYP450 and or P-gp glycoprotein might lead to increased plasma concentrations of doxorubicin and thereby increased toxicity.
- Clozapine may increase the risk/severity of the haematological toxicity of doxorubicin.
- Doxorubicin may reduce the oral bioavailability of digoxin.
- The safety of immunisation with live or attenuated viral vaccines following obinutuzumab has not been studied and vaccination with live virus vaccines is not recommended during treatment and until B-cell recovery.
- Please consult the relevant summary of product characteristics via <https://www.medicines.org.uk/emc> for the full list of interactions.

Treatment Schedule:

Day	Drug	Dose	Route	Diluent and rate
CYCLE 1				
1	Dexamethasone	20mg	IV	To be administered as a slow IV bolus - 60 minutes prior to the infusion May be omitted if oral prednisolone given at least 60 minutes before Obinutuzumab dose
	Paracetamol	1000mg	PO	To be administered 30 minutes prior to the infusion
	Chlorphenamine	10mg	IV	Bolus – to be administered 30 minutes prior to the infusion
	Obinutuzumab	1000mg	IV	In 250mL Sodium Chloride 0.9% (see rate below)
	Prednisolone	100mg	PO	Orally once a day for 5 days
	Cyclophosphamide	750mg/m²	IV	In 250mL Sodium Chloride 0.9% over 30 minutes

Issue Date: 13 th September 2019 Review Date: September 2022	Page 5 of 11	Protocol reference: MPHAOCHOHA
Author: Hannah Greaves	Authorised by: Drug & Therapeutics Committee/ Dave Breen	Version No: 1.0

	Doxorubicin	50mg/m²	IV	In 100mL Sodium Chloride 0.9% over 30 minutes
	Vincristine*	1.4mg/m² (max 2mg dose)	IV ONLY	In 50mL Sodium Chloride 0.9% over 5-10 minutes – fatal is given any other route
8	Paracetamol	1000mg	PO	To be administered 30 minutes prior to the infusion
	Chlorphenamine	10mg	IV	Bolus – to be administered 30 minutes prior to the infusion
	Obinutuzumab	1000mg	IV	In 250ml Sodium Chloride 0.9% (see rate below)
15	Paracetamol	1000mg	PO	To be administered 30 minutes prior to the infusion
	Chlorphenamine	10mg	IV	Bolus – to be administered 30 minutes prior to the infusion
	Obinutuzumab	1000mg	IV	In 250ml Sodium Chloride 0.9% (see rate below)
CYCLE 2-6				
1	Paracetamol	1000mg	PO	To be administered 30 minutes prior to the infusion
	Chlorphenamine	10mg	IV	Bolus – to be administered 30 minutes prior to the infusion
	Obinutuzumab	1000mg	IV	In 250ml Sodium Chloride 0.9%
	Prednisolone	100mg	PO	Orally once a day for 5 days
Day	Drug	Dose	Route	Diluent and rate
CYCLE 2-6 continued				
	Cyclophosphamide	750mg/m²	IV	In 250mL Sodium Chloride 0.9% over 30 minutes
	Doxorubicin	50mg/m²	IV	In 100mL Sodium Chloride 0.9% over 30 minutes
	Vincristine*	1.4mg/m² (max 2mg dose)	IV ONLY	In 50mL Sodium Chloride 0.9% over 5-10 minutes – fatal is given any other route
CYCLE 7 and 8				
1	Paracetamol	1000mg	PO	To be administered 30 minutes prior to the infusion
	Chlorphenamine	10mg	IV	Bolus – to be administered 30 minutes prior to the infusion

	Obinutuzumab	1000mg	IV	In 250ml Sodium Chloride 0.9% (see rate below)
--	---------------------	---------------	----	--

Cycle frequency is every 21 days up to a maximum of 8 cycles

Patients may then be eligible for Obinutuzumab maintenance therapy – please refer to separate protocol.

Patients with a Grade 3 IRRs with the previous infusion should have intravenous corticosteroid at least 1 hour prior to the next obinutuzumab infusion.

Management of IRRs may require temporary interruption, reduction in the rate of infusion, or treatment discontinuations or obinutuzumab as outlined below.

- Grade 4 (life threatening): Infusion must be stopped, and therapy must be permanently discontinued.
- Grade 3 (severe): Infusion must be temporarily stopped and symptoms treated. Upon resolution of symptoms, the infusion can be restarted at no more than half the previous rate (the rate being used at the time that the IRR occurred) and, if the patient does not experience any IRR symptoms, the infusion rate escalation can resume at the increments and intervals as appropriate for the treatment dose. The infusion must be stopped and therapy permanently discontinued if the patient experiences a second occurrence of a Grade 3 IRR.
- Grade 1-2 (mild to moderate): The infusion rate must be reduced and symptoms treated. Infusion can be continued upon resolution of symptoms and, if the patient does not experience any IRR symptoms, the infusion rate escalation can resume at the increments and intervals as appropriate for the treatment dose.

Obinutuzumab rate:

First dose: Administer at 50mg/hour – the rate of infusion can be escalated in 50mg/hr increments every 30 minutes to a maximum of 400mg/hr. Incremental escalation of the infusion rate should be considered only in the absence of Infusion Related Reactions (IRRs).

Subsequent doses: If no IRR or if an IRR Grade 1 occurred during the previous infusion when the final infusion rate was 100 mg/hr or faster, infusions can be started at a rate of 100 mg/hr and increased by 100 mg/hr increments every 30 minutes to a maximum of

Issue Date: 13 th September 2019 Review Date: September 2022	Page 7 of 11	Protocol reference: MPHACHOHA
Author: Hannah Greaves	Authorised by: Drug & Therapeutics Committee/ Dave Breen	Version No: 1.0

400 mg/hr. If the patient experienced an IRR of Grade 2 or higher during the previous infusion administer at 50 mg/hr. The rate of infusion can be escalated in 50 mg/hr increments every 30 minutes to a maximum of 400mg/hr.

Monitor observations as routine including 30 minutes after each dose increment to identify infusion reactions. Incremental escalation of the infusion rate should be considered only in the absence of Infusion Related Reactions (IRRs).

Main Toxicities:

Induction treatment with Obinutuzumab

Upper respiratory tract infection, sinusitis, urinary tract infection, pneumonia, herpes zoster, oral herpes, rhinitis, pharyngitis, lung infection, influenza nasopharyngitis, squamous cell carcinoma of the skin, neutropenia, thrombocytopenia, anaemia, leukopenia, tumour lysis syndrome, hyperuricaemia, hypokalaemia, insomnia, depression, anxiety, headache, ocular hyperaemia, atrial fibrillation and cardiac failure, hypertension, cough, nasal congestion, rhinorrhoea, diarrhoea, constipation, alopecia, pruritus, dysuria, urinary incontinence, pyrexia, asthenia, chest pain, reduction in WCCs and neutropenia, weight increase and infusion related reactions.

Tumour lysis syndrome (TLS) prophylaxis: Patients with a high tumour burden and/or renal impairment ($\text{CrCl} < 70\text{mL/min}$) are considered at risk of TLS and should receive prophylaxis. Prophylaxis should consist of adequate hydration and administration of uricostatics (e.g. allopurinol), or suitable alternative treatment such as urate oxidase (e.g. rasburicase), starting 12-24 hours prior to start of obinutuzumab infusion as per standard practice. Patients should continue to receive repeated prophylaxis prior to each subsequent infusion, if deemed appropriate.

Hypotension: it is important to note that hypotension is a symptom of the potential infusion related reaction (IRR), which may occur during obinutuzumab intravenous infusions. **Therefore, withholding of antihypertensive treatments should be considered for 12 hours prior to and throughout each infusion and for the first hour after administration.**

Issue Date: 13 th September 2019 Review Date: September 2022	Page 8 of 11	Protocol reference: MPHA0CHOHA
Author: Hannah Greaves	Authorised by: Drug & Therapeutics Committee/ Dave Breen	Version No: 1.0

Investigations and treatment plan

	Pre	Cycle 1 D1	Cycle 1 D8	Cycle 1 D15	Cycle 2	Cycle 3	Ongoing
Informed Consent	x						
Hepatitis B core antibody and surface antigens & Hep C & HIV 1+2	x						
Clinical Assessment	x	x			x	x	Every cycle
SACT Assessment (to include toxicities)	x	x	x	x	x	x	Prior to every dose
Weight	x	x			x	x	Every cycle
Height	x						
FBC	x	x			x	x	Every cycle
U&E, LFT and Bone profile	x	x			x	x	Every cycle
Creatinine Clearance (Cockcroft and Gault)	x						
Blood pressure	x	x	x	x	x	x	Continuous monitoring required if on Obinutuzumab
Temp, respiratory rate, pulse		x	x	x	x	x	Continuous monitoring required if on Obinutuzumab
PS recorded	x	x			x	x	Prior to every dose
Pregnancy test	x						Where appropriate
Bone marrow assessment							Where clinically indicated
Radiological imaging	x						Repeat end of treatment
ECHO or MUGA scan							Before treatment in patients over 60 or with pre-existing cardiac disease

Issue Date: 13 th September 2019 Review Date: September 2022	Page 9 of 11	Protocol reference: MPHACHOHA
Author: Hannah Greaves	Authorised by: Drug & Therapeutics Committee/ Dave Breen	Version No: 1.0

Dose Modifications and Toxicity Management:

Haematological toxicity

Note: no dose modifications required for first cycle	
Neutrophils (x10⁹/L)	Modification
<1 on day of treatment	Delay cycle by 1 week. Discuss use of G-CSF or dose reductions for further cycles with consultant
Any febrile neutropenia following any cycle of CHOP	All subsequent cycles should be given with GCSF support. Consider dose reduction.
Febrile neutropenic episode despite G-CSF support	Consider reduction of cyclophosphamide and doxorubicin by 50% for all subsequent cycles
Platelets (x10⁹/L)	Modification
<100 on day of treatment	Delay cycle by 1 week.
Second delay due to thrombocytopenia	Consider reducing dose of cyclophosphamide and doxorubicin by 50% for all subsequent cycles

Neutropenia: Patients who experience neutropenia should be closely monitored with regular laboratory tests until resolution. If treatment is necessary it should be administered in accordance with local guidelines and the administration G-CSF should be considered. Any signs of concomitant infection should be treated appropriately. Dose delays should be considered in case of severe or life threatening neutropenia. It is strongly recommended that patients with severe neutropenia lasting more than 1 week receive antimicrobial prophylaxis throughout the treatment period until resolution to Grade 1 or 2. Antiviral and antifungal prophylaxis should be considered. Late onset neutropenia (occurring ≥ 28 days after the end of treatment) or prolonged neutropenia (lasting more than 28 days after treatment has been completed/stopped) may occur. Patients with renal impairment ($\text{CrCl} < 50\text{mL/min}$) are more at risk of neutropenia.

Thrombocytopenia: Severe and life-threatening thrombocytopenia including acute thrombocytopenia (occurring within 24 hours after the infusion) has been observed during treatment with obinutuzumab. Fatal haemorrhagic events have also been

Issue Date: 13 th September 2019 Review Date: September 2022	Page 10 of 11	Protocol reference: MPHAOCHOHA
Author: Hannah Greaves	Authorised by: Drug & Therapeutics Committee/ Dave Breen	Version No: 1.0

reported in Cycle 1 in patients treated with obinutuzumab. Patients should be closely monitored for thrombocytopenia, especially during the first cycle; regular laboratory tests should be performed until the event resolves, and dose delays should be considered in case of severe or life-threatening thrombocytopenia.

Non-Haematological toxicity

Neurotoxicity:

Grade	Modification
Grade 2 motor weakness or grade 3 sensory toxicity	Dose reduce Vincristine to 50%
Higher grades of neurological toxicity	Omit Vincristine

References:

1. Summary of Product Characteristics, Gazyvaro 1000mg concentrate for solution for infusion, Roche, available from <https://www.medicines.org.uk/emc> [accessed on the 16th August 2019]
2. Summary of Product Characteristics, Vincristine Sulphate 1mg/ml, Hospira UK Ltd, available from <https://www.medicines.org.uk/emc> [accessed on the 16th August 2019]
3. Summary of Product Characteristics, Doxorubicin 2mg/mL Concentrate for solution for infusion, Accord Healthcare Limited, available from <https://www.medicines.org.uk/emc> [accessed on the 16th August 2019]
4. Summary of Product Characteristics, Cyclophosphamide 500mg powder for solution for injection or infusion, Sandoz Limited, available from <https://www.medicines.org.uk/emc> [accessed on the 16th August 2019]
5. NICE TA 513 Obinutuzumab for untreated advanced follicular lymphoma – Published 21 March 2018
6. Marcus R., Davies A., Obinutuzumab for the First Line Treatment of Follicular Lymphoma. The New England Journal of Medicine, 2017; 377: 1331-1344

Issue Date: 13 th September 2019 Review Date: September 2022	Page 11 of 11	Protocol reference: MPHACHOHA
Author: Hannah Greaves	Authorised by: Drug & Therapeutics Committee/ Dave Breen	Version No: 1.0